Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan thoracic oncology group study 0402

Japanese Journal of Clinical Oncology

Volumn 41, Issue 8, 2011, Pages 948-952

  Kobayashi, Masashi ^a   Matsui, Kaoru ^a   Katakami, Nobuyuki ^b   Takeda, Koji ^c   Moriyama, Adusa ^d   Iwamoto, Yasuo ^e   Takada, Minoru ^f   Yoshioka, Hiroshige ^g   Sueoka Aragane, Naoko ^h   Nakagawa, Kazuhiko ^f  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d Rinku General Medical Center   (Japan)

^e HIROSHIMA CITY HOSPITAL   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KURASHIKI CENTRAL HOSPITAL   (Japan)

^h SAGA UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; Elderly; Gefitinib; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEMALE; GERIATRIC PATIENT; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERSTITIAL LUNG DISEASE; JAPAN; LIVER DYSFUNCTION; LUNG ADENOCARCINOMA; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SMOKING; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANEMIA; ANOREXIA; ANTINEOPLASTIC AGENTS; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TREATMENT OUTCOME;

EID: 79961048416     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr087     Document Type: Article

References (24)

1. Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007;25:5570-7.
2. Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-46.
3. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-medicare. J Clin Oncol 2004;22:4971-8.
4. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2191-7.
5. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
6. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-72.
7. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
9. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
10. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
11. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
12. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006;11:190-8.
13. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005;11:3032-7.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
15. Common Toxicity Criteria, Version 2.0. April 30, 1999. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf. (1 October 2010, date last accessed).
16. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
18. Satouchi M, Ishii G, Todo T, Whiteley J, Donald E, McCormack R, et al. Validation study of epidermal growth factor receptor (EGFR) mutation tests using bronchofiberscopic brushing cytology samples and pleural effusion from non-small-cell lung cancer (NSCLC) patients in the diagnostic setting. Ann Oncol 2010;21(Suppl. 8):viii129.
19. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: Controversies and opportunities. Cancer Cytopathol 2011;119:80-91.
20. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52.
21. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.
22. Crino' L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008;26:4253-60.
23. Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, et al. A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:1166-71.
24. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56.